
|Articles|September 1, 2002
TIMs make impact on infants
Winston-Salem, N.C. - Separate studies involving atopic dermatitis drugs tacrolimus (Protopic) and pimecrolimus (Elidel) show the topical immunomodulators (TIMs) are safe and effective for off-label use on children under age 2.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Shows Durable Skin Clearance in Phase 3 Psoriasis Extension
2
The Emerging Role of Oral Peptide Therapeutics in Psoriasis and Beyond
3
Social Media Mythbusters: Hydrocolloid Pimple Patches
4
Allergan Aesthetics Refreshes APP Loyalty Program for Aesthetic Practices
5










